Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.

Incyte Expands Portfolio with $750 Million Acquisition of Escient, a Pioneer in Immune and Neuro Biotechnology

Incyte, Escient, biotechnology, immune system, neuroscience, acquisition, deal, $750 million, portfolio expansion, drug development, therapeutics, GPCR targets.